BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 15, 2009
 |  BioCentury  |  Product Development

Trius claims a zolid case

Generic vancomycin is the first-line drug of choice for complicated skin and skin structure infections, but physicians are increasingly turning to Pfizer Inc.'s Zyvox linezolid thanks to its high clinical cure rates and the increasing prevalence of vancomycin-resistant bacterial strains. Trius Therapeutics Inc. believes its second-generation oxazolidinone, called torezolid, will have higher potency and a better resistance profile than Zyvox.

Torezolid fared well in a Phase II trial, results of which were announced last week, setting the stage for a Phase III program to begin early next year.

In the double-blind, U.S. trial in 164 evaluable patients, 200, 300 and 400 mg oral torezolid given once daily for 5-7 days produced clinical cure rates of 98%, 94% and 94% at 7-14 days after the last dose. Methicillin-resistant Staphylococcus aureus (MRSA) was identified as the primary pathogen in 72%...

Read the full 689 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >